NORWALK, Conn., Dec. 11, 2014 /PRNewswire/ — UBM Medica US announces that OncoTherapy Network, a leading online community to help oncologists and other clinicians gain a better understanding of the newest information available regarding the use of targeted therapies and immunotherapies, discusses some of the latest research on prostate cancer.
While the Movember campaign for men’s health awareness may technically be over, prostate cancer continues to be a growing concern for men all year long. With prostate cancer being the most common cancer among men, research must continue in order to detect and determine the aggressiveness of tumors, along with having better targeted treatment options available.
Recent exclusive coverage on OncoTherapy Network discusses the newest developments in prostate cancer biomarkers and targeted treatments:
- Prostate Cancer Screening – What Does the Evidence Tell Us?: In May 2012, the United States Preventive Services Task Force (USPSTF) released a recommendation against prostate-specific antigen (PSA) screening for men.
- Reducing Recurrence With a New Prostate Cancer Vaccine: For those patients diagnosed with localized prostate cancer, the risk of recurrence is approximately 30%–even years after initial treatment.
- Prostate Cancer Resistance: Focus on AR-V7: As cancer treatment continues to get more targeted, the search for reliable biomarkers to identify patients most likely to benefit from this novel and expensive therapy is essential.
About UBM Medica US
Addressing today’s healthcare information needs, UBM Medica US, delivers strategic, integrated communications solutions and comprehensive reach — online, in print, via custom programs and live events. Improving the effectiveness of healthcare through information and education, UBM Medica US provides unbiased clinical, practical, and business information for physicians, providers and payers resulting in improved quality of care for patients around the world. Through journals, magazines, online communities, live and digital events, and other valuable resources, UBM Medica US also delivers comprehensive communication solutions for the pharmaceutical and related industries. Online communities include CancerNetwork.com, ConsultantLive.com, DiagnosticImaging.com, RheumatologyNetwork.com, OBGYN.net, PhysiciansPractice.com, PsychiatricTimes.com and SearchMedica.com. UBM Medica US is part of UBM Americas which, through a range of aligned interactive environments, both physical and digital – increases business effectiveness for both customers and audiences through meaningful experiences, knowledge and connections. Headquartered in New York, UBM Americas brings together UBM’s healthcare business, UBM Medica US; UBM Tech’s technology communities, live events and custom services; UBM Canon’s advanced design and manufacturing event, online and print brands; UBM Connect New York’s catering, cruise shipping, contact-center management, and fine, specialty and custom chemical communities; and UBM Mexico’s concrete, construction and hospitality services shows. For more information, visit www.UBMMedicaUS.com.
About UBM plc
UBM plc is a global events-led marketing services and communications company. We help businesses do business, bringing the world’s buyers and sellers together at events and online, as well as producing and distributing news and specialist content. Our 5,500 staff in more than 30 countries are organized into expert teams which serve commercial and professional communities, helping them to do business and their markets to work effectively and efficiently.
For more information, go to www.ubm.com; follow us on Twitter at @UBM_plc to get the latest UBM corporate news.
Jason J. Golden
Content Marketing Manager
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncotherapy-network-highlights-the-latest-in-prostate-cancer-300008495.html
SOURCE UBM Medica US